twitter twitter

Bio Ascend

Atlanta Lung Cancer Symposium Agenda

Agenda Coming Soon!

Those with approved access can enter their access code. 

Please be advised that only paid registrants and attendees of of this symposium will be provided access to this downloadable content.

October 26, 2024

7:55 AM
Welcome and Introductions
Suresh Ramalingam, MD, FACP, FASCO
Ticiana A. Leal, MD

Plenary 1: Locally Advanced/Advanced NSCLC/SCLC

Co-Chairs: Ioana Bonta, MD

8:00 AM
Small Cell Lung Cancer: New Therapeutic Advances in 2024
Taofeek K. Owonikoko, MD, PhD

8:20 AM

First Line Therapy for Advanced NSCLC Without Driver Mutations
Julie Brahmer, MD
8:40 AM
Salvage Therapy for Advanced NSCLC: Reasons for Hope?
Karen L. Reckamp, MD

9:00 AM

Locally Advanced NSCLC: Radiotherapy Considerations
Sibo Tian, MD

9:20 AM

Locally advanced NSCLC: Role of IO and Emerging Advances
Ticiana Leal, MD

9:40 AM

Clinical Case Panel Discussion
Oncology Fellow – Mosun Oyenuga, MD, MPH
10:00 AM
Morning Break and Exhibits

Plenary 2: Early-Stage NSCLC

Co-Chairs: Mohan Krishnamachary, MD, and Ticiana Leal, MD

10:20 AM
Neoadjuvant Therapy for Resectable NSCLC
Paul Bunn, MD

10:40 AM

Early-Stage NSCLC: When is Sub-Lobar Resection Appropriate?
Onkar Khullar, MD, MSc

11:00 AM

Adjuvant Therapy for Oncogene-Addicted NSCLC
Jamie Chaft, MD

11:20 AM

DEBATE: Should Adjuvant IO be Given After Surgery Following Chemo-IO
Yes: John Heymach, MD, PhD
No: Stephen Liu, MD

12:00 AM

Lunch Symposium

Plenary 3: Targeted Therapy in Advanced NSCLC I

Co-Chairs: William S. Jonas, MD, and Jennifer W. Carlisle, MD

12:45 PM

EGFR Inhibition in Locally Advanced and Stage IV NSCLC
Suresh Ramalingam, MD, FACP, FASCO

1:05 PM

Treatment of ALK-Positive Advanced NSCLC
Shirish M. Gadgeel, MD

1:25 PM

KRAS Inhibition in Advanced NSCLC
John Heymach, MD, PhD

1:45 PM

Panel Discussion

2:05 PM

Afternoon Break and Exhibits

Plenary 4: Targeted Therapy in Advanced NSCLC II and Rare Thoracic Malignancies

Co-Chairs: Paul Gill, MD, and Michael B. Andrews, MD

2:25 PM

Liquid Biopsy: Current and Future Applications
David Gandara

2:40 PM

EGFR Exon 20 Insertion and Uncommon EGFR Mutations

Jennifer W. Carlisle, MD

2:55 PM

RET, MET and ROS1: Optimal Therapy and Emerging Agents

Conor E. Steuer, MD

3:10 PM

Systemic Therapy for HER-2, BRAF and NTRK

Greg J. Riely, MD, PhD

3:25 PM

Rare Thoracic Malignancies: Mesothelioma and Thymic Malignancies

Fatemeh Ardeshir, MD, MSc

3:40 PM

Panel Discussion

3:55 PM

Closing Remarks and Adjourn

We use cookies for various purposes including enabling website functionality and targeted marketing activities. For more information about cookies, please review our Privacy & Cookie Notice.